DUBLIN, July 6, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Overactive Bladder Therapeutics Market 2017-2021" report to their offering.
The global Overactive Bladder (OAB) Therapeutics market to grow at a CAGR of 1.56% during the period 2017-2021.
Global Overactive Bladder (OAB) Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.
The latest trend gaining momentum in the market is advancing biomedical science. In the past few decades, the advancement in science and introduction of nanotechnologies in the global pharmaceutical market have revolutionized the development of medicines. With a better understanding of the pathogenesis of disease at genetic and molecular levels has led to the discovery of new targets for therapy, thus producing disease-modifying drugs. Modern techniques such as bioinformatics, molecular targeting, nanotechnology, and personalized medicines have facilitated drug development in the area of neurodegenerative disorders.
According to the report, one of the major drivers for this market is growing geriatric population. OAB is a chronic disorder, characterized by increased frequency of urination and nocturia. Several studies have revealed that the risk of developing OAB increases with age and is most common among the older population. Also, as the disorder is non-life threatening in nature, it has been observed that the probability of complying with the medication treatment for OAB is high among older patients than in adults aged lesser than 55 years.
Further, the report states that one of the major factors hindering the growth of this market is Rise in economic burden of OAB. Urinary incontinence (involuntary loss of urine), stress urinary incontinence (involuntary loss of urine accompanied by increased abdominal pressure), and OAB (increased urgency, frequency, and nocturia) represents a major public healthcare concern. OAB affects one out of seven US adults, and the prevalence of the disease is equal to both men and women. The lack of disease-modifying drugs for the treatment of OAB unnecessarily prolongs the treatment duration, thus increasing treatment cost. Also, the rise in geriatric population in the US too increases the economic burden of disease on individuals and payers.
- Astellas Pharma
- Hisamitsu Pharmaceutical
Other prominent vendors
- Ion Channel Innovations
- Kwang Dong Pharmaceutical
- Lanzhou Institute of Biological Products
- ONO Pharmaceutical
- Teva Pharmaceutical Industries
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Research Methodology
Part 04: Introduction
Part 05: Market landscape
Part 06: Pipeline analysis
Part 07: Market segmentation based on drug class
Part 08: Drug profile of key OAB therapeutics
Part 09: Geographical segmentation
Part 10: Decision framework
Part 11: Drivers and challenges
Part 12: Market trends
Part 13: Vendor landscape
Part 14: Key vendor analysis
Part 15: Appendix
For more information about this report visit https://www.researchandmarkets.com/research/fmglvp/global_overactive
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets